Impact of anti-proliferative drugs and mesh size of active stents on coronary angioplasty results at 1 year

Project summary

CONTEXT

The use of new anti-proliferative drugs other than Plaquitaxel or Sirolimus as well as the design of finer meshes have been significant advances in the field of design of new active stents.

GOALS

To evaluate the clinical impact of angioplasties with active stent implantation with different mesh sizes and different anti-proliferative substances.

Evaluate the clinical impact of the two groups (fine mesh vs. thick mesh).

METHODOLOGY

Inclusion of any coronary angioplasty with use of active stent